Patents by Inventor Peter Carmeliet
Peter Carmeliet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10106601Abstract: The present application relates to the field of leukemias, and more in particular to how P1 GF inhibition can help to treat Philadelphia chromosome positive (Ph+) leukemias. Methods are provided for treating Ph+ leukemias by administering P1 GF inhibitors. Also disclosed are uses of P1 GF inhibitors in the treatment of Ph+ leukemias, or for the preparation of a medicament against Ph+ leukemias.Type: GrantFiled: October 2, 2009Date of Patent: October 23, 2018Assignees: VIB VZW, Life Sciences Research Partners VZWInventors: Peter Carmeliet, Sonja Loges
-
Publication number: 20170066822Abstract: The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determining the genotype of VEGFR-1 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGFR-1 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGFR-1 gene.Type: ApplicationFiled: November 17, 2016Publication date: March 9, 2017Inventors: Peter Carmeliet, Sanne Lysbet de Haas, Diether Lambrechts, Stefan Scherer
-
Publication number: 20160193192Abstract: The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor.Type: ApplicationFiled: November 30, 2015Publication date: July 7, 2016Inventors: Peter Carmeliet, Frederik De Smet, Joost Schymkowitz, Frédéric Rousseau, Corentin Herbert
-
Publication number: 20160166532Abstract: This disclosure relates to the field of angiogenesis, more particularly to the field of pathological angiogenesis. In particular, the disclosure has found that inhibitors reducing the activity of the enzyme carnitine palmitoyltransferase 1A can be used for treatment of diseases in which pathological angiogenesis is involved. In particular, the disclosure provides siRNAs directed against carnitine palmitoyltransferase 1A for the treatment of pathological angiogenesis. The disclosure also provides the use of a therapeutically effective amount of inhibitors of carnitine palmitoyltransferase 1A, or a pharmaceutically acceptable salt thereof, for the treatment of pathological angiogenesis.Type: ApplicationFiled: July 25, 2014Publication date: June 16, 2016Applicant: Life Sciences Research Partners VZWInventors: Peter Carmeliet, Sandra Schoors
-
Patent number: 9234025Abstract: The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor.Type: GrantFiled: July 2, 2010Date of Patent: January 12, 2016Assignees: SANOFI, VIB VZW, LIFE SCIENCES RESEARCH PARTNERS VZW, VRIJE UNIVERSITEIT BRUSSELInventors: Peter Carmeliet, Frederik De Smet, Joost Schymkowitz, Frédéric Rousseau, Corentin Herbert
-
Patent number: 9085617Abstract: The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.Type: GrantFiled: February 3, 2014Date of Patent: July 21, 2015Assignees: THROMBOGENICS N.V., VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW, LIFE SCIENCES RESEARCH PARTNERS VZWInventors: Jean-Marie Stassen, Peter Carmeliet, Desire Collen
-
Publication number: 20150004136Abstract: The invention is concerned with a method of determining whether a patient is more suitably treated by a therapy with an angiogenesis inhibitor, such as bevacizumab, by determining the genotype of VEGFR-1 gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of VEGFR-1 gene. The invention further relates to a method for improving the treatment effect of chemotherapy of a patient suffering from cancer by adding an angiogenesis inhibitor, such as bevacizumab, based on the genotype of VEGFR-1 gene.Type: ApplicationFiled: May 22, 2014Publication date: January 1, 2015Applicants: Hoffmann-La Roche Inc., VIB vzwInventors: Peter Carmeliet, Sanne Lysbet de Haas, Diether Lambrechts, Stefan Scherer
-
Publication number: 20140178397Abstract: The present invention provides novel monoclonal antibodies directed to P1GF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.Type: ApplicationFiled: February 3, 2014Publication date: June 26, 2014Inventors: Jean-Marie STASSEN, Peter CARMELIET, Desire COLLEN
-
Patent number: 8758748Abstract: The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.Type: GrantFiled: December 20, 2010Date of Patent: June 24, 2014Assignees: Thrombogenics N.V., VLAAMS Interuniversitair Instituut voor Biotechnologie VZW, Life Sciences Research Partners VZWInventors: Jean-Marie Stassen, Peter Carmeliet, Désiré Collen
-
Patent number: 8741862Abstract: A key function of blood vessels, to supply oxygen, is impaired in tumors because of abnormalities in their endothelial lining. PHD proteins serve as oxygen sensors and may regulate oxygen delivery. Therefore the role of endothelial PHD2 in vessel shaping by implanting tumors in PHD2+/? mice was studied. Haplodeficiency of PHD2 did not affect tumor vessel density or lumen size, but normalized the endothelial lining and vessel maturation. This resulted in improved tumor perfusion and oxygenation, and inhibited tumor cell invasion, intravasation and metastasis. Haplodeficiency of PHD2 redirected the specification of endothelial tip cells to a more quiescent phenotype of a filopodia-lacking “phalanx” cell type. Without being bound to a particular mechanism, this transition could at least in part be explained by upregulation of (soluble) VEGFR-1 and VE-cadherin.Type: GrantFiled: January 20, 2010Date of Patent: June 3, 2014Assignees: VIB VZW, Life Science Research Partners VZWInventors: Peter Carmeliet, Massimiliano Mazzone
-
Publication number: 20130183310Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: ApplicationFiled: March 5, 2013Publication date: July 18, 2013Inventors: Peter Carmeliet, Desire Collen, Sandro De Falco, Ruvo Menotti
-
Publication number: 20130177565Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: ApplicationFiled: March 5, 2013Publication date: July 11, 2013Applicants: LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP), VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB)Inventors: Peter CARMELIET, Desire Collen, Sandro De Falco, Ruvo Menotti
-
Publication number: 20130177564Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: ApplicationFiled: March 5, 2013Publication date: July 11, 2013Inventors: Peter CARMELIET, Desire Collen, Sandro De Falco, Ruvo Menotti
-
Publication number: 20130078224Abstract: The disclosure relates to the field of ischemia and how to increase tissue perfusion in ischemic tissue by cellular therapy. Specifically, the beneficial effects of myeloid (bone marrow-derived) cells with a particular arteriogenic gene expression profile are shown, and it is shown that increased arteriogenesis and perfusion is specifically due to the effects of combined PDGFB and SDF-1. The arteriogenic gene profile of the myeloid cells used for therapy can, for instance, be obtained by inhibition of PHD2.Type: ApplicationFiled: March 30, 2011Publication date: March 28, 2013Applicants: LIFE SCIENCES RESEARCH PARTNERS VZW, VIB VZWInventors: Massimiliano Mazzone, Peter Carmeliet
-
Publication number: 20120263710Abstract: The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF?/?) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.Type: ApplicationFiled: May 14, 2012Publication date: October 18, 2012Applicants: LIFE SCIENCES RESEARCH PARTNERS VZW (LSRP), VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW (VIB)Inventors: Peter CARMELIET, Désiré Collen, Sandro De Falco, Ruvo Menotti
-
Publication number: 20120195858Abstract: The present invention relates to methods for improving the overall survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the vascular endothelial growth factor receptor 1 (VEGFR-1) gene. The present invention further provides methods for improving the progression-free survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the VEGFR-1 gene. The present invention also provides for methods for assessing the responsiveness of a patient to an angiogenesis inhibitor by determining the presence of one or more variant alleles of the VEGFR-1 gene.Type: ApplicationFiled: August 3, 2010Publication date: August 2, 2012Inventors: Dorothee Foernzler, Paul Delmar, Stefan Scherer, Diether Lambrechts, Peter Carmeliet
-
Publication number: 20120094864Abstract: The present invention relates to an extracellular binding domain for an allosteric inhibitor, whereby said binding domain is derived from a single membrane span tyrosine kinase receptor. More specifically, the invention relates to an extracellular domain derived from a Fibroblast Growth Factor Receptor (FGFR). It further relates to the use of this domain for the identification of similar domains in the extracellular part of other tyrosine kinase receptors, and to a screening method for identification of a small compound allosteric inhibitor.Type: ApplicationFiled: July 2, 2010Publication date: April 19, 2012Applicants: SANOFI, VRIJE UNIVERSITEIT BRUSSEL, LIFE SCIENCES RESEARCH PARTNERS VZW, VIB VZWInventors: Peter Carmeliet, Frederik De Smet, Joost Schymkowitz, Frédéric Rousseau, Corentin Herbert
-
Publication number: 20120022135Abstract: A key function of blood vessels, to supply oxygen, is impaired in tumors because of abnormalities in their endothelial lining. PHD proteins serve as oxygen sensors and may regulate oxygen delivery. Therefore the role of endothelial PHD2 in vessel shaping by implanting tumors in PHD2+/? mice was studied. Haplodeficiency of PHD2 did not affect tumor vessel density or lumen size, but normalized the endothelial lining and vessel maturation. This resulted in improved tumor perfusion and oxygenation, and inhibited tumor cell invasion, intravasation and metastasis. Haplodeficiency of PHD2 redirected the specification of endothelial tip cells to a more quiescent phenotype of a filopodia-lacking “phalanx” cell type. Without being bound to a particular mechanism, this transition could at least in part be explained by upregulation of (soluble) VEGFR-1 and VE-cadherin.Type: ApplicationFiled: January 20, 2010Publication date: January 26, 2012Applicants: LIFE SCIENCES RESEARCH PARTNERS VZW, VIB VZWInventors: Peter Carmeliet, Massimiliano Mazzone
-
Publication number: 20110288020Abstract: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)—a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons.Type: ApplicationFiled: December 3, 2010Publication date: November 24, 2011Inventors: Peter Carmeliet, Désiré Collen, Bert Oosthuyse
-
Publication number: 20110250209Abstract: The present application relates to the field of leukemias, and more in particular to how P1 GF inhibition can help to treat Philadelphia chromosome positive (Ph+) leukemias. Methods are provided for treating Ph+ leukemias by administering P1 GF inhibitors. Also disclosed are uses of P1 GF inhibitors in the treatment of Ph+ leukemias, or for the preparation of a medicament against Ph+ leukemias.Type: ApplicationFiled: October 2, 2009Publication date: October 13, 2011Applicants: LIFE SCIENCES RESEARCH PARTNERS VZW, VIB VZWInventors: Peter Carmeliet, Sonja Loges